SARS-CoV-2-specific monoclonal antibody AER002 in Long COVID: an exploratory randomized phase 2a mechanistic trial.

What was studied

This exploratory trial tested the antibody AER002 in long COVID. It was placebo-controlled and double-blind. 36 people took part. They met the WHO case definition of long COVID. Each got a single infusion and was followed for 360 days. The main outcome was a physical health score at 90 days.

What they found

AER002 was reported as safe and well tolerated. No significant differences were found between groups. This covered physical health, quality of life, function, thinking and blood markers. A post-hoc analysis looked at antibody levels. Some people felt a benefit. They had lower baseline antibody levels and higher drug exposure.

What it means for patients

The authors say AER002 did not work in this proof-of-concept study. They say the findings could inform future trials of antibodies aimed at viral persistence.

Why it is not certain yet

This was a small trial of 36 people. It was exploratory. The benefit finding came from a post-hoc analysis. Long COVID has no proven treatments, per the abstract. The abstract does not give a plan for next steps.

Source

SARS-CoV-2-specific monoclonal antibody AER002 in Long COVID: an exploratory randomized phase 2a mechanistic trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.